<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006938.pub3" GROUP_ID="SYMPT" ID="363205091616190680" MERGED_FROM="" MODIFIED="2014-11-27 16:11:16 +0000" MODIFIED_BY="Anna Hobson" NOTES="&lt;p&gt;SD 29/111/09: The note from reviewer said &amp;quot;&lt;span class=&quot;marker&quot;&gt;PLEASE STATE WHAT MEASUREMENT SCALES WILL BE USED FOR SOME OF THESE OUTCOMES&amp;quot; &lt;/span&gt; but as stated, we did not plan to exclude any study on the basis of the outcome measure used. There are numerous scales used for each of these outcomes and I do not think it is appropriate to list all of them here.&lt;/p&gt;" NOTES_MODIFIED="2014-11-27 16:11:16 +0000" NOTES_MODIFIED_BY="Anna Hobson" REVIEW_NO="163" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.2">
<COVER_SHEET MODIFIED="2014-11-27 16:11:16 +0000" MODIFIED_BY="Anna Hobson">
<TITLE>Droperidol for treatment of nausea and vomiting in palliative care patients</TITLE>
<CONTACT>
<PERSON ID="A48EBF6082E26AA2002589C3D5C23099" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Saskie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dorman</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Palliative Medicine</POSITION>
<EMAIL_1>saskie.dorman@poole.nhs.uk</EMAIL_1>
<EMAIL_2>saskiedorman@doctors.org.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Palliative Medicine</DEPARTMENT>
<ORGANISATION>Poole Hospital NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Longfleet Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Poole</CITY>
<ZIP>BH15 2JB</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1202 448118</PHONE_1>
<PHONE_2>+44 1202 448115</PHONE_2>
<FAX_1>+44 1202 448119</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-11-27 16:11:07 +0000" MODIFIED_BY="Anna Hobson">
<PERSON ID="z1403121454235757662211788773874" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Jemma</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Storrar</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jemchalmers@doctors.org.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Wessex Higher Training Programme Palliative Medicine</DEPARTMENT>
<ORGANISATION/>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Wessex</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1403121455386087381676372257669" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Morwenna</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hitchens</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>mhitchens@doctors.org.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Wessex Higher Training Programme Palliative Medicine</DEPARTMENT>
<ORGANISATION/>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Wessex</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1403121505353731494743022181102" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Tracey</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Platt</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>tplatt@doctors.org.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Wessex Higher Training Programme Palliative Medicine</DEPARTMENT>
<ORGANISATION/>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Wessex</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="A48EBF6082E26AA2002589C3D5C23099" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Saskie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dorman</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Palliative Medicine</POSITION>
<EMAIL_1>saskie.dorman@poole.nhs.uk</EMAIL_1>
<EMAIL_2>saskiedorman@doctors.org.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Palliative Medicine</DEPARTMENT>
<ORGANISATION>Poole Hospital NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Longfleet Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Poole</CITY>
<ZIP>BH15 2JB</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1202 448118</PHONE_1>
<PHONE_2>+44 1202 448115</PHONE_2>
<FAX_1>+44 1202 448119</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-11-27 15:06:10 +0000" MODIFIED_BY="Anna Hobson">
<UP_TO_DATE>
<DATE DAY="19" MONTH="11" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="11" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2020"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="10" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-11-27 16:11:16 +0000" MODIFIED_BY="Anna Hobson">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2014-11-27 16:11:16 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="26" MONTH="11" YEAR="2014"/>
<DESCRIPTION>
<P>This review will be assessed for further updating in 2020 as it is unlikely that new evidence will be published.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-11-26 14:23:57 +0000" MODIFIED_BY="Anna Hobson">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-11-26 14:23:53 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="19" MONTH="11" YEAR="2013"/>
<DESCRIPTION>
<P>No additional studies were identified for inclusion in this update, and the conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-11-26 14:23:57 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="19" MONTH="11" YEAR="2013"/>
<DESCRIPTION>
<P>This review has been updated to include the results of a new search. Change of authorship.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-08-15 11:45:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-12 09:24:12 +0000" MODIFIED_BY="Jessica Thomas">
<DATE DAY="5" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-08-15 12:33:08 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-02-22 20:42:28 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-02-22 20:41:06 +0000" MODIFIED_BY="[Empty name]">
<NAME>Poole Hospital NHS Foundation Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Library services</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2014-02-22 20:41:54 +0000" MODIFIED_BY="[Empty name]">
<NAME>Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Library Services</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2014-02-22 20:42:28 +0000" MODIFIED_BY="[Empty name]">
<NAME>Southampton University Hospital Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Library Services</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-08-15 12:33:08 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-08-15 12:33:08 +0100" MODIFIED_BY="[Empty name]">
<NAME>The Cochrane Collaboration</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Searches and editorial review</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-11-17 11:49:34 +0000" MODIFIED_BY="Anna Hobson">
<SUMMARY MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<TITLE MODIFIED="2009-10-05 17:00:59 +0100" MODIFIED_BY="[Empty name]">Droperidol for the treatment of nausea and vomiting (sickness) in people with advanced disease</TITLE>
<SUMMARY_BODY MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Nausea (a feeling of sickness) and vomiting are common and distressing symptoms for people with advanced cancer and other life-threatening illnesses. Several medications to control these symptoms are available. Droperidol is one example, which has been used to try to prevent or treat nausea and vomiting for people having surgery or chemotherapy. In our search updated in November 2013 we found no randomised studies of droperidol for the treatment of nausea or vomiting for people receiving palliative care or suffering from an incurable progressive medical condition. Several studies reported on the use of droperidol for the prevention of nausea and vomiting associated with chemotherapy. Further studies are needed to find out which medications are most suitable to treat nausea and vomiting in palliative care.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-11-17 11:49:18 +0000" MODIFIED_BY="Anna Hobson">
<ABS_BACKGROUND MODIFIED="2014-11-17 11:49:18 +0000" MODIFIED_BY="Anna Hobson">
<P>This is an updated version of the original Cochrane review published in Issue 10, 2010, on droperidol for the treatment of nausea and vomiting in palliative care patients. Nausea and vomiting are common symptoms in patients with terminal illness and can be very unpleasant and distressing. There are several different types of antiemetic treatments that can be used to control these symptoms. Droperidol is an antipsychotic drug and has been used and studied as an antiemetic in the management of postoperative and chemotherapy nausea and vomiting.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-05-04 18:50:07 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and adverse events (both minor and serious) associated with the use of droperidol for the treatment of nausea and vomiting in palliative care patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>We searched electronic databases including CENTRAL, MEDLINE (1950-), EMBASE (1980-), CINAHL (1981-) and AMED (1985-), using relevant search terms and synonyms. The basic search strategy was ("droperidol" OR "butyrophenone") AND ("nausea" OR "vomiting"), modified for each database. We updated the search on 2 December 2009. We performed updated searches of MEDLINE, EMBASE, CENTRAL and AMED 2009 to 2013 on 19 November 2013 and of CINAHL on 20 November 2013. We also searched trial registers (<I>meta</I>Register of controlled trials (www.controlled-trials.com/mrct), clinicaltrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/)) on 22 November 2013, using the keyword "droperidol".</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Randomised controlled trials (RCTs) of droperidol for the treatment of nausea or vomiting, or both, in adults receiving palliative care or suffering from an incurable progressive medical condition.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>We judged the potential relevance of studies based on their titles and abstracts, and obtained studies that we anticipated might meet the inclusion criteria. Two review authors independently reviewed the abstracts for the initial review and four review authors reviewed the abstracts for the update to assess suitability for inclusion. We discussed discrepancies to achieve consensus.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>The 2010 search strategy identified 1664 abstracts (and 827 duplicates) of which we obtained 23 studies in full as potentially meeting the inclusion criteria. On review of the full papers, we identified no studies that met the inclusion criteria.</P>
<P>The updated searches carried out in November 2013 identified 304 abstracts (261 excluding duplicates) of which we obtained 18 references in full as potentially meeting the inclusion criteria. On review of the full papers, we identified no studies that met the inclusion criteria, therefore there were no included studies in this review.</P>
<P>We found no registered trials of droperidol for the management of nausea or vomiting in palliative care.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-11-17 11:45:35 +0000" MODIFIED_BY="Anna Hobson">
<P>Since first publication of this review, no new studies were found. There is insufficient evidence to advise on the use of droperidol for the management of nausea and vomiting in palliative care. Studies of antiemetics in palliative care settings are needed to identify which agents are most effective, with minimum side effects.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-11-17 11:49:34 +0000" MODIFIED_BY="Anna Hobson">
<BACKGROUND MODIFIED="2014-11-17 11:49:34 +0000" MODIFIED_BY="Anna Hobson">
<P>This is an updated version of the original Cochrane review published in Issue 10, 2010, on droperidol for the treatment of nausea and vomiting in palliative care patients.</P>
<P>Nausea and vomiting are common symptoms in patients with terminal illness and can be very distressing.</P>
<P>Between 40% and 70% of patients with advanced cancer are thought to suffer from nausea or vomiting (<LINK REF="REF-Twycross-1998" TYPE="REFERENCE">Twycross 1998</LINK>), and these symptoms are also common in other terminal conditions (<LINK REF="REF-Edmonds-2001" TYPE="REFERENCE">Edmonds 2001</LINK>; <LINK REF="REF-Klinkenberg-2004" TYPE="REFERENCE">Klinkenberg 2004</LINK>). Antiemetic drugs can help control symptoms while the medical team undertakes an assessment of the patient and tries to treat the underlying cause. There are many such causes in patients with terminal illness, including the underlying illness (for example, bowel obstruction or metastases in the liver), biochemical disturbance (for example, renal failure or hypercalcaemia) or drugs (for example, when starting morphine). Several causes of nausea and vomiting may coexist in an individual patient. Doctors try to choose the best first choice antiemetic based on what is thought to be the underlying cause (<LINK REF="REF-Bentley-2001" TYPE="REFERENCE">Bentley 2001</LINK>), using a second line antiemetic if the first is not effective. An antiemetic such as levomepromazine, which has effect at several receptors relevant to nausea and vomiting, is often used as a second line antiemetic.</P>
<P>Whilst the choice of first line antiemetic based on the likely cause of symptoms is a widespread approach, there is little evidence from randomised controlled trials for many of the drugs used for these symptoms in this patient group (for example, cyclizine, haloperidol or levomepromazine) (<LINK REF="REF-Davis-2010" TYPE="REFERENCE">Davis 2010</LINK>; <LINK REF="REF-Glare-2004" TYPE="REFERENCE">Glare 2004</LINK>).</P>
<P>Droperidol is one example of an antiemetic that may be used to try to reduce nausea and vomiting (<LINK REF="REF-Rhodes-2001" TYPE="REFERENCE">Rhodes 2001</LINK>). It is in the butyrophenone class of drugs and acts as a dopamine antagonist at the chemoreceptor trigger zone in the brain (<LINK REF="REF-Mannix-2004" TYPE="REFERENCE">Mannix 2004</LINK>). Theoretically, therefore, it should be effective for biochemical causes of nausea or to reduce the emetic effect of drugs such as morphine, which is mediated through the chemoreceptor trigger zone. Haloperidol is another example of a butyrophenone and its use in this context has been systematically reviewed separately (<LINK REF="REF-Perkins-2009" TYPE="REFERENCE">Perkins 2009</LINK>). Droperidol is used alone or together with other antiemetics orally, intravenously or intramuscularly.</P>
<P>In the UK, droperidol is available as an injection (2.5 mg in 1 mL), licensed for intravenous use for the prevention and treatment of postoperative nausea and vomiting (PONV) or the prevention of nausea and vomiting induced by morphine derivatives during postoperative patient-controlled analgesia (PCA). For PONV the dose is 0.625 mg to 1.25 mg in adults (0.625 mg for the elderly or those with renal or hepatic impairment). For use with PCA in adults, the dose is 15 to 50 micrograms of droperidol per mg of morphine, up to a maximum daily dose of 5 mg of droperidol. There are no data on PCA for patients with renal or hepatic impairment in the Summary of Product Characteristics (SPC).</P>
<P>The United States Food and Drug Administration issued a black box warning in 2001 following concerns about QT interval prolongation and deaths due to cardiac arrhythmia with the use of droperidol (<LINK REF="REF-Food-and-Drug-Administration-2001" TYPE="REFERENCE">Food and Drug Administration 2001</LINK>). This decision has been the focus of debate (<LINK REF="REF-Habib-2008" TYPE="REFERENCE">Habib 2008</LINK>; <LINK REF="REF-Kao-2003" TYPE="REFERENCE">Kao 2003</LINK>; <LINK REF="REF-Ludwin-2008" TYPE="REFERENCE">Ludwin 2008</LINK>; <LINK REF="REF-Nuttall-2007" TYPE="REFERENCE">Nuttall 2007</LINK>). The UK Medicines and Healthcare products Regulatory Authority (MHRA) raised concerns about the potential effect of droperidol on the QT interval and requested a risk-benefit analysis, which led to the voluntary withdrawal of some formulations of droperidol by Jansen-Cilag (<LINK REF="REF-MHRA-2001" TYPE="REFERENCE">MHRA 2001</LINK>). The MHRA subsequently granted marketing authorisation for droperidol to the pharmaceutical company ProStrakan, in January 2008 (<LINK REF="REF-MHRA-2008" TYPE="REFERENCE">MHRA 2008</LINK>).</P>
<P>Droperidol is also known by its trade names Droleptan (Australia, New Zealand), Inapsine (US, Canada), Xomolix (UK), Droperdal (Brazil), Dehydrobenzperidol (Belgium, Luxembourg), Droperol (India), Sintodian (Italy), Dridol (Norway, Sweden), Inapsin (South Africa), Paxical (South Africa) and Dehidrobenzperidol (Spain, Portugal) (<LINK REF="REF-Martindale-2009" TYPE="REFERENCE">Martindale 2009</LINK>).</P>
<P>The medical literature regarding droperidol as an antiemetic relates primarily to its use intravenously in the prevention of postoperative nausea and vomiting or chemotherapy-associated nausea and vomiting. We wanted to establish whether there was any evidence to support its use in the palliative care setting.</P>
<P>All patients with terminal illness should have access to palliative care, independent of their diagnosis, and we wish to reflect this in our review. Defining this population has been identified as a problem in previous reviews. We used the definition 'adult patients in any setting, receiving palliative care or suffering an incurable progressive medical condition', which has previously been used in a Cochrane review (<LINK REF="REF-Hirst-2001" TYPE="REFERENCE">Hirst 2001</LINK>).<I>
<BR/>
</I>
</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the efficacy and adverse events (both minor and serious) associated with the use of droperidol for the treatment of nausea and vomiting in palliative care patients.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<SELECTION_CRITERIA MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs) of droperidol for the treatment of nausea or vomiting, or both, in any setting.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-06-15 14:58:01 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Adults receiving palliative care or suffering from an incurable progressive medical condition. Adults suffering from nausea or vomiting, or both.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>Nausea or vomiting, or both, thought to be secondary to pregnancy or surgery; antiemetic(s) used for the prophylaxis of nausea or vomiting associated with chemotherapy.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>We included studies where droperidol was used to treat nausea or vomiting (alone or in addition to other agents) including any dose of droperidol, via any route, over any duration of follow-up.</P>
<SUBSECTION>
<HEADING LEVEL="4">Acceptable comparators</HEADING>
<UL>
<LI>Placebo</LI>
<LI>Other drug</LI>
<LI>Non-pharmacological intervention</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<OL>
<LI>Nausea rating: intensity, duration (the patient's report of his or her symptoms)</LI>
<LI>Vomiting severity rating (the patient's report of his or her symptoms)</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<OL>
<LI>Quality of life measurement</LI>
<LI>Acceptability of treatment</LI>
<LI>Need for rescue antiemetic medication</LI>
<LI>Adverse events (including sedation, rigidity, tremor and cardiovascular side effects)</LI>
<LI>Withdrawal from study because of side effects</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>We searched electronic databases including CENTRAL, MEDLINE, EMBASE, CINAHL and AMED, using relevant search terms and synonyms. The basic search strategy was ("droperidol" OR "butyrophenone") AND ("nausea" OR "vomiting"), modified for each database. Handsearching complemented the electronic searches (using reference lists of included studies, relevant chapters and review articles). We did not impose a language restriction on studies. The MEDLINE search strategy is shown in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. The search was undertaken on 23 November 2007 and updated 16 June 2009 and again on 2 December 2009.</P>
<P>We performed updated searches of MEDLINE, EMBASE, CENTRAL and AMED 2009 to 2013 on 19 November 2013 and of CINAHL on 20 November 2013.</P>
<P>We also searched trial registers (<I>meta</I>Register of controlled trials (<A HREF="http://www.controlled-trials.com/mrct">www.controlled-trials.com/mrct</A>), clinicaltrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>)) on 22 November 2013, using the keyword "droperidol".</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>We judged the potential relevance of studies based on their titles and abstracts, and obtained studies that we anticipated might meet the inclusion criteria. Two review authors independently reviewed the abstracts for the initial review and four review authors reviewed the abstracts for the update to assess suitability for inclusion. We discussed discrepancies to achieve consensus. For the initial review, a translator enabled us to assess whether two Japanese papers identified by the search met the inclusion criteria for the review (<LINK REF="STD-Fujii-1987" TYPE="STUDY">Fujii 1987</LINK>; <LINK REF="STD-Niijima-1986" TYPE="STUDY">Niijima 1986</LINK>). We planned to assess the quality of included papers using the Jadad criteria (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<STUDY_DESCRIPTION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>The search strategy run on 23 November 2007 identified 1851 abstracts (1021 excluding duplicates), of which we obtained 23 references in full as potentially meeting the inclusion criteria. On review of the full papers, we identified no studies that met the inclusion criteria. We identified a further 140 abstracts when the search was updated on 16 June 2009 and we identified 48 abstracts when the search was further updated on 2 December 2009.</P>
<P>From assessment of these additional abstracts, none met the inclusion criteria.</P>
<P>The updated searches carried out in November 2013 identified 304 abstracts (261 excluding duplicates), of which we obtained 18 references in full as potentially meeting the inclusion criteria. On review of the full papers, we identified no studies that met the inclusion criteria, therefore there were no studies included in the review.</P>
<P>We found no registered trials of droperidol for the management of nausea or vomiting in palliative care. The study flow diagram is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>We excluded 41 studies (23 from the 2010 review and 18 from the updated 2013 search) and these are detailed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>We included no studies.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-11-29 15:51:53 +0000" MODIFIED_BY="[Empty name]">
<P>It was not possible to draw conclusions about the effects of droperidol in the palliative care setting as we could find no included studies for this review.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="2">Evidence for the effectiveness of droperidol</HEADING>
<P>Droperidol has been widely used as an antiemetic, particularly for the prophylaxis and treatment of postoperative nausea and vomiting (PONV), and it has been studied for the prophylaxis of nausea and vomiting associated with chemotherapy (e.g. cisplatin).</P>
<P>Droperidol for postoperative nausea and vomiting has been systematically reviewed (<LINK REF="REF-Carlisle-2006" TYPE="REFERENCE">Carlisle 2006</LINK>), and there is some evidence for its effectiveness in this context. Carlisle's systematic review identified 222 studies examining the effectiveness of droperidol for PONV. The relative risk (compared to placebo) was 0.65 for nausea and 0.65 for vomiting. A systematic review of antiemetics for the control of PONV for patients receiving patient-controlled analgesia found that droperidol was significantly more effective than placebo (<LINK REF="STD-Tramer-1999" TYPE="STUDY">Tramer 1999</LINK>), with numbers needed to treat of 2.7 for nausea (confidence interval 1.8 to 5.2) and 3.1 for vomiting (confidence interval 2.3 to 4.8), compared to placebo.</P>
<P>Of the studies reporting the effectiveness of droperidol for the prevention of nausea and vomiting associated with chemotherapy (<LINK REF="STD-Aapro-1991" TYPE="STUDY">Aapro 1991</LINK>; <LINK REF="STD-Fujii-1987" TYPE="STUDY">Fujii 1987</LINK>; <LINK REF="STD-Herrstedt-1991" TYPE="STUDY">Herrstedt 1991</LINK>; <LINK REF="STD-Jacobs-1980" TYPE="STUDY">Jacobs 1980</LINK>; <LINK REF="STD-Kim-1994" TYPE="STUDY">Kim 1994</LINK>; <LINK REF="STD-Lehoczky-2001" TYPE="STUDY">Lehoczky 2001</LINK>; <LINK REF="STD-Lennox-1985" TYPE="STUDY">Lennox 1985</LINK>; <LINK REF="STD-Lewis-1984" TYPE="STUDY">Lewis 1984</LINK>; <LINK REF="STD-Melsom-1982" TYPE="STUDY">Melsom 1982</LINK>; <LINK REF="STD-Minegishi-2003" TYPE="STUDY">Minegishi 2003</LINK>; <LINK REF="STD-Muller-1989" TYPE="STUDY">Muller 1989</LINK>; <LINK REF="STD-Niijima-1986" TYPE="STUDY">Niijima 1986</LINK>; <LINK REF="STD-Owens-1984" TYPE="STUDY">Owens 1984</LINK>; <LINK REF="STD-Poka-1993" TYPE="STUDY">Poka 1993</LINK>; <LINK REF="STD-Roberts-1985" TYPE="STUDY">Roberts 1985</LINK>; <LINK REF="STD-Sagae-2003" TYPE="STUDY">Sagae 2003</LINK>; <LINK REF="STD-Saller-1986" TYPE="STUDY">Saller 1986</LINK>; <LINK REF="STD-Stuart_x002d_Harris--1983" TYPE="STUDY">Stuart-Harris 1983</LINK>), one included only participants in the palliative stage of their illness. This was a cross-over study of 32 in-patients with advanced lung cancer receiving cisplatin chemotherapy (<LINK REF="STD-Fujii-1987" TYPE="STUDY">Fujii 1987</LINK>). The addition of droperidol to dexamethasone and metoclopramide was reported to be associated with a shorter median duration of nausea (two days versus four days, P value &lt; 0.05), but no significant difference in median vomiting duration or volume. However, randomisation, allocation concealment and blinding methods were not clear.</P>
<P>The use of droperidol as an antiemetic has also been studied in patients with severe non-malignant low back pain who were treated with an epidural catheter (<LINK REF="STD-Aldrete-1995" TYPE="STUDY">Aldrete 1995</LINK>), and in patients attending the emergency department who received treatment of nausea or vomiting due to any cause (<LINK REF="STD-Braude-2006" TYPE="STUDY">Braude 2006</LINK>; <LINK REF="STD-Patanwala-2010" TYPE="STUDY">Patanwala 2010</LINK>).</P>
<P>It is not clear to what extent these studies can be extrapolated to the palliative care setting and other causes of nausea and vomiting.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Side effects</HEADING>
<P>In 2001, the United States Food and Drug Administration issued a black box warning against the use of droperidol, in view of case reports of prolongation of the QT interval, and cardiac arrhythmia and sudden death (<LINK REF="REF-Food-and-Drug-Administration-2001" TYPE="REFERENCE">Food and Drug Administration 2001</LINK>).</P>
<P>This has been an area of controversy, with several authors subsequently defending the use of droperidol (<LINK REF="REF-McKeage-2006" TYPE="REFERENCE">McKeage 2006</LINK>; <LINK REF="REF-Nuttall-2007" TYPE="REFERENCE">Nuttall 2007</LINK>). A full review of the relevant literature is beyond the scope of this systematic review.</P>
<P>Other side effects reported in the literature (in the context of postoperative nausea and vomiting and chemotherapy-associated nausea and vomiting) include drowsiness or sedation, akathisia, dystonia, anxiety or restlessness, euphoria, hypotension, flush, dry mouth or rigor (<LINK REF="STD-Aapro-1991" TYPE="STUDY">Aapro 1991</LINK>; <LINK REF="STD-Braude-2006" TYPE="STUDY">Braude 2006</LINK>; <LINK REF="STD-Jacobs-1980" TYPE="STUDY">Jacobs 1980</LINK>; <LINK REF="STD-Roberts-1985" TYPE="STUDY">Roberts 1985</LINK>; <LINK REF="STD-Sagae-2003" TYPE="STUDY">Sagae 2003</LINK>; <LINK REF="STD-Saller-1986" TYPE="STUDY">Saller 1986</LINK>). Since droperidol is often given with other medication in these settings it can be difficult to establish causality. Sedation appears to be the most commonly reported side effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Droperidol in palliative care</HEADING>
<P>Despite previous widespread use and research in anaesthesia and oncology, we did not find any published evidence from randomised controlled trials of the use of droperidol in palliative care settings. A letter by Thangathurai asserts the usefulness of droperidol for the palliation of nausea and vomiting (<LINK REF="STD-Thangathurai-2010" TYPE="STUDY">Thangathurai 2010</LINK>). Haloperidol (like droperidol, a butyrophenone) is more commonly used in palliative care within the UK and its use for the management of nausea and vomiting in palliative care has been systematically reviewed separately (<LINK REF="REF-Perkins-2009" TYPE="REFERENCE">Perkins 2009</LINK>).</P>
<P>Studies of antiemetics in palliative care settings are needed to identify which agents are most effective, with minimum side effects (<LINK REF="REF-Davis-2010" TYPE="REFERENCE">Davis 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Systematic reviews and the evidence base in palliative care</HEADING>
<P>Previous systematic reviews in palliative care have been beset by the problem of the lack of evidence from original studies, particularly randomised controlled trials. Cochrane systematic reviews in palliative care published up to December 2007 were reviewed by <LINK REF="REF-Wee-2008" TYPE="REFERENCE">Wee 2008</LINK>, who concluded that "Cochrane reviews in palliative care ... fail to provide good evidence for clinical practice because the primary studies are few in number, small, clinically heterogeneous, and of poor quality and external validity". It can be difficult to carry out randomised controlled trials in palliative care (<LINK REF="REF-Grande-2000" TYPE="REFERENCE">Grande 2000</LINK>), and other methodological approaches may be useful in this context. However, Hadley et al note that good quality observational studies are also sparse (<LINK REF="REF-Hadley-2009" TYPE="REFERENCE">Hadley 2009</LINK>).</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-11-17 11:46:08 +0000" MODIFIED_BY="Anna Hobson">
<IMPLICATIONS_PRACTICE MODIFIED="2014-11-17 11:46:08 +0000" MODIFIED_BY="Anna Hobson">
<P>Since first publication of this review, no new studies were found. There is insufficient evidence from randomised controlled trials at present to advise on the use of droperidol for the management of nausea and vomiting in palliative care.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Studies of antiemetics in palliative care settings are needed to identify which agents are most effective, with minimum side effects.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-11-17 11:38:30 +0000" MODIFIED_BY="Anna Hobson">
<P>For the 2010 review we would like to thank the staff of the Cochrane Pain, Palliative &amp; Supportive Care Review Group, including Jessica Thomas, Yvonne Roy, Anna Hobson, Sylvia Bickley for help with refining the search strategy, Caroline Struthers for updating the search, Mari Imamura for translation of two Japanese papers, and our peer referees, Giovambattista Zeppetella and Janet Wale, who commented on the draft of the protocol for this systematic review, and Karl Gallegos, Gerhild Becker and Andrew Moore who commented on the review. Thanks also to Linda Porter and Lyn Jackson (pharmacists) and Susan Merner (librarian) at Poole Hospital NHS Foundation Trust.</P>
<P>For the updated 2013 review we would like to thank Jo Abbott (Trials Search Co-ordinator), Jane Hayes, Yvonne Roy, Mike Bennett and Phil Wiffen at The Cochrane Collaboration. We would also like to thank the librarians at the Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust and Barbara Peirce at Poole Hospital NHS Foundation Trust.</P>
<P>Cochrane Review Group funding acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane PaPaS Group. Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, National Health Service (NHS) or the Department of Health.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-11-17 11:38:21 +0000" MODIFIED_BY="Anna Hobson">
<P>JS: None known.</P>
<P>MH: None known.</P>
<P>TP: None known.</P>
<P>SD: None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>SD and Paul Perkins designed the original systematic review. SD and Sylvia Bickley developed the search strategy with comments from PP. SD and PP independently reviewed all titles and abstracts yielded by the search strategy (2010) and discussed any discrepancies to achieve a consensus. JS, MH and TP independently reviewed all abstracts yielded by the updated searches (2013); full papers were reviewed independently by JS, MH, TP and SD. JS, MH and TP updated the text of the review which SD wrote in 2010 with input from PP. SD is the corresponding author and contact for future updates.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-06-16 08:30:37 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded studies of antiemetics used for the prophylaxis of nausea or vomiting associated with chemotherapy.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-10-08 18:23:38 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-11-12 13:52:03 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-08-15 12:23:29 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-10-04 18:59:49 +0100" MODIFIED_BY="[Empty name]"/>
<EXCLUDED_STUDIES MODIFIED="2014-08-15 12:23:29 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aapro-1991" MODIFIED="2009-05-03 14:15:42 +0100" MODIFIED_BY="[Empty name]" NAME="Aapro 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-05-03 14:15:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aapro MS, Froidevaux P, Roth A, Alberto P</AU>
<TI>Antiemetic efficacy of droperidol or metoclopramide combined with dexamethasone and diphenhydramine</TI>
<SO>Oncology</SO>
<YR>1991</YR>
<VL>48</VL>
<PG>116-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aldrete-1995" MODIFIED="2009-11-29 16:16:37 +0000" MODIFIED_BY="[Empty name]" NAME="Aldrete 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-11-29 16:16:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aldrete J</AU>
<TI>Reduction of nausea and vomiting from epidural opioids by adding droperidol to the infusate in home-bound patients</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>7</NO>
<PG>544-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braude-2006" MODIFIED="2009-05-03 15:27:12 +0100" MODIFIED_BY="[Empty name]" NAME="Braude 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-03 15:27:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braude D, Soliz T, Crandall C, Hendey G, Andrews J, Weichental L</AU>
<TI>Antiemetics in the ED: a randomized controlled trial comparing 3 common agents</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>177-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-05-03 14:12:05 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-2011" MODIFIED="2014-08-15 12:15:38 +0100" MODIFIED_BY="[Empty name]" NAME="Casey 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 12:15:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Casey C, Chen LM, Rabow MW</AU>
<TI>Symptom management in gynaecologic malignancies</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>7</NO>
<PG>1077-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheung-2011" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Cheung 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheung WY, Zimmermann C</AU>
<TI>Pharmacologic management of cancer-related pain, dyspnea and nausea</TI>
<SO>Seminars in Oncology</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>3</NO>
<PG>450-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dale-2011" MODIFIED="2014-08-15 12:18:41 +0100" MODIFIED_BY="[Empty name]" NAME="Dale 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 12:18:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dale O, Moksnes K, Kaasa S</AU>
<TI>European Palliative Care Research Collaborative Pain Guidelines: Opioid switching to improve analgesia or reduce side effects. A systematic review</TI>
<SO>Palliative Medicine</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>5</NO>
<PG>494-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Etievant-2010" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Etievant 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Etievant A, Betry C, Haddjeri N</AU>
<TI>Partial dopamine D2 / serotonin 5HT-1a receptor agonists as new therapeutic agents</TI>
<SO>Open Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>3</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feyer-2011" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Feyer 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feyer P, Jordan K</AU>
<TI>Update and new trends in antiemetic therapy: the continuing need for novel therapies</TI>
<SO>Annals of Oncology</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>1</NO>
<PG>30-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujii-1987" MODIFIED="2014-08-15 12:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Fujii 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-08-15 12:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fujii M, Kiura K, Kamei H, Okabe K, Toki H</AU>
<TI>Antiemetic effects of combinations of metoclopramide, dexamethasone and dexamethasone for the prevention of cisplatin-induced gastrointestinal toxicity: a randomized crossover trial [Japanese]</TI>
<SO>Gan To Kagaku Ryoho</SO>
<YR>1987</YR>
<VL>14</VL>
<NO>7</NO>
<PG>2257-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Getto-2011" MODIFIED="2014-08-15 12:18:52 +0100" MODIFIED_BY="[Empty name]" NAME="Getto 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 12:18:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Getto L, Zeserson E, Breyer M</AU>
<TI>Vomiting, diarrhea, constipation and gastroenteritis</TI>
<SO>Emergency Medicine Clinics of North America</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>2</NO>
<PG>211-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glare-2011" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Glare 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glare P, Miller J, Nikolova T, Tickoo R</AU>
<TI>Treating nausea and vomiting in palliative care: a review</TI>
<SO>Clinical Interventions in Aging</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>1</NO>
<PG>243-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzales-2011" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Gonzales 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzales MJ, Widera E</AU>
<TI>Nausea and other non-pain symptoms in long-term care</TI>
<SO>Clinics in Geriatric Medicine</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>2</NO>
<PG>213-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hardy-2010" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Hardy 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hardy JR, O'Shea A, White C, Gilshenan K, Welch L, Douglas C</AU>
<TI>The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer</TI>
<SO>Journal of Pain &amp; Symptom Management</SO>
<YR>2010</YR>
<VL>40</VL>
<NO>1</NO>
<PG>111-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrstedt-1991" MODIFIED="2014-08-15 12:19:03 +0100" MODIFIED_BY="[Empty name]" NAME="Herrstedt 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-08-15 12:19:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrstedt J, Hannibal J, Hallas J, Andersen E, Laursen LC, Hansen M</AU>
<TI>High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting</TI>
<SO>Annals of Oncology</SO>
<YR>1991</YR>
<VL>2</VL>
<PG>223-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-1980" MODIFIED="2009-05-03 14:20:46 +0100" MODIFIED_BY="[Empty name]" NAME="Jacobs 1980" YEAR="1980">
<REFERENCE MODIFIED="2009-05-03 14:20:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs AJ, Deppe G, Cohen CJ</AU>
<TI>A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotherapy with cis-platinum</TI>
<SO>Gynecologic Oncology</SO>
<YR>1980</YR>
<VL>10</VL>
<PG>55-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-1994" MODIFIED="2014-08-15 12:19:11 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-08-15 12:19:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim H, Rosenberg SA, Steinberg SM, Cole DJ, Weber JS</AU>
<TI>A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2</TI>
<SO>Journals of Immunotherapy</SO>
<YR>1994</YR>
<VL>16</VL>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehoczky-2001" MODIFIED="2009-10-08 18:24:17 +0100" MODIFIED_BY="[Empty name]" NAME="Lehoczky 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-10-08 18:24:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehoczky O, Bagameri A, Sarosi Z, Kulcsar T, Pulay T</AU>
<TI>Does the addition of an anxiolytic drug improve the antiemetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting?</TI>
<TO>Fokozhato-e a szteroid es granisetron antiemeticus kombinacio hatekonysaga anxiolyticus szer hozzaadasaval a cisplatin okozta hanyas profilaxisaban?</TO>
<SO>Orvosi Hetilap</SO>
<YR>2001</YR>
<VL>142</VL>
<PG>1681-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lennox-1985" MODIFIED="2009-05-03 14:26:50 +0100" MODIFIED_BY="[Empty name]" NAME="Lennox 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-05-03 14:26:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lennox B, Reid M, McCaffrey D, Miaskowski C, Kaplan BH, Vogl SE</AU>
<TI>Randomized double-blind crossover trial of prochlorperazine (P) alone versus prochlorperazine plus droperidol (D) for emesis prophylaxis in patients (PTS) receiving intravenous bolus cis-platinum (DDP)</TI>
<SO>Proceedings of American Association of Cancer Research</SO>
<YR>1985</YR>
<VL>26</VL>
<PG>189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1984" MODIFIED="2009-05-03 14:29:10 +0100" MODIFIED_BY="[Empty name]" NAME="Lewis 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-05-03 14:29:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis GO, Bernath AM, Ellison NM, Gallagher JG, Porter PA, Rine KT</AU>
<TI>Double-blind crossover trial of droperidol, metoclopramide, and prochlorperazine as antiemetics in cisplatin therapy</TI>
<SO>Clinical Pharmacy</SO>
<YR>1984</YR>
<VL>3</VL>
<PG>618-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McHugh-2011" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="McHugh 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McHugh ME, Miller-Saultz D</AU>
<TI>Assessment and management of gastrointestinal symptoms in advanced illness</TI>
<SO>Primary Care - Clinics in Office Practice</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>2</NO>
<PG>225-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McNicol-2003" MODIFIED="2014-08-15 12:19:59 +0100" MODIFIED_BY="[Empty name]" NAME="McNicol 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-15 12:19:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McNicol A, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al</AU>
<TI>Management of opioid side effects in cancer-related and chronic non-cancer pain: a systematic review</TI>
<SO>Journal of Pain</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>5</NO>
<PG>231-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melsom-1982" MODIFIED="2009-05-03 14:37:43 +0100" MODIFIED_BY="[Empty name]" NAME="Melsom 1982" YEAR="1982">
<REFERENCE MODIFIED="2009-05-03 14:37:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melsom H, Nandrup E, Monge OR</AU>
<TI>Metoclopramide (Primperan) versus droperidol (Dridol) as an antiemetic in intravenous cancer chemotherapy</TI>
<TO>Metoklopramid (Primperan) versus droperidol (Dridol) som antiemetikum ved intravenos cancerkjemoterapi</TO>
<SO>Tidsskrift for Den Norske Laegeforening</SO>
<YR>1982</YR>
<VL>102</VL>
<NO>16</NO>
<PG>914-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minegishi-2003" MODIFIED="2014-08-15 12:20:18 +0100" MODIFIED_BY="[Empty name]" NAME="Minegishi 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-15 12:20:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minegishi Y, Ohmatsu H, Miyamoto T, Niho S, Goto K, Kubota K, et al</AU>
<TI>Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study</TI>
<SO>European Journal of Cancer</SO>
<YR>2004</YR>
<VL>40</VL>
<PG>1188-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1989" MODIFIED="2009-05-03 14:46:56 +0100" MODIFIED_BY="[Empty name]" NAME="Muller 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-05-03 14:46:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller G, Konig H</AU>
<TI>Antiemetic efficacy of high-dose metoclopramide and high-dose droperidol in preventing cisplatin-induced nausea and emesis: a single-blind comparison</TI>
<SO>Blut</SO>
<YR>1989</YR>
<VL>59</VL>
<NO>3</NO>
<PG>280</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niijima-1986" MODIFIED="2014-08-15 12:20:51 +0100" MODIFIED_BY="[Empty name]" NAME="Niijima 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-08-15 12:20:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niijima T, Isurugi K, Akaza H, Kondon Y, Kawabe K, Fujita K, et al</AU>
<TI>Randomised cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy [Japanese]</TI>
<SO>Gan To Kagaku Ryoho</SO>
<YR>1986</YR>
<VL>13</VL>
<NO>7</NO>
<PG>2376-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Connor-2011" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="O'Connor 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Connor B, Creedon B</AU>
<TI>Pharmacological treatment of bowel obstruction in cancer patients</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2011</YR>
<VL>12</VL>
<NO>14</NO>
<PG>2205-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Owens-1984" MODIFIED="2014-08-15 12:21:08 +0100" MODIFIED_BY="[Empty name]" NAME="Owens 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-08-15 12:21:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Owens NJ, Schauer AR, Nightingale CH, Golub GR, Martin RS, Williams HM, et al</AU>
<TI>Antiemetic efficacy of prochlorperazine, haloperidol, and droperidol in cisplatin-induced emesis</TI>
<SO>Clinical Pharmacy</SO>
<YR>1984</YR>
<VL>3</VL>
<PG>167-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patanwala-2010" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Patanwala 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patanwala AE, Amini R, Hays DP, Rosen P</AU>
<TI>Antiemetic therapy for nausea and vomiting in the emergency department</TI>
<SO>Journal of Emergency Medicine</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>3</NO>
<PG>330-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poka-1993" MODIFIED="2014-08-15 12:21:35 +0100" MODIFIED_BY="[Empty name]" NAME="Poka 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-08-15 12:21:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poka R, Hernadi Z, Juhasz B, Lampe L</AU>
<TI>Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>1993</YR>
<VL>42</VL>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richards-2011" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Richards 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richards JR, Richards IN, Ozery G, Derlet RW</AU>
<TI>Droperidol analgesia for opioid-tolerant patients</TI>
<SO>Journal of Emergency Medicine</SO>
<YR>2011</YR>
<VL>41</VL>
<NO>4</NO>
<PG>389-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-1985" MODIFIED="2009-05-03 14:59:29 +0100" MODIFIED_BY="[Empty name]" NAME="Roberts 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-05-03 14:59:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts WS, Wisniewski BJ, Cavanagh D, Marsden DE</AU>
<TI>Droperidol as an antiemetic in cis-platinum-induced nausea and vomiting</TI>
<SO>Oncology</SO>
<YR>1985</YR>
<VL>42</VL>
<PG>42-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sagae-2003" MODIFIED="2014-08-15 12:21:58 +0100" MODIFIED_BY="[Empty name]" NAME="Sagae 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-15 12:21:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sagae S, Ishioka S, Fukunaka N, Terasawa K, Kobayashi K, Sugmara M, et al</AU>
<TI>Combination therapy with granisetron, methylprednisolone and droperidol as an antiemetic prophylaxis in CDDP-induced delayed emesis for gynaecologic cancer</TI>
<SO>Oncology</SO>
<YR>2003</YR>
<VL>64</VL>
<PG>46-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saller-1986" MODIFIED="2014-08-15 12:22:25 +0100" MODIFIED_BY="[Empty name]" NAME="Saller 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-08-15 12:22:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saller R, Hellenbrcht D</AU>
<TI>High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis</TI>
<SO>European Journal of Cancer and Clinical Oncology</SO>
<YR>1986</YR>
<VL>22</VL>
<NO>10</NO>
<PG>1199-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2010" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith T, Paice J, Ritter J, Bobb B</AU>
<TI>An evidence-based approach to cutaneous treatment of nausea, pain and neuropathy in palliative care</TI>
<SO>Journal of Pain &amp; Symptom Management</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>2</NO>
<PG>372-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2011" MODIFIED="2014-08-15 12:23:16 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 12:23:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith T, Ritter JK, Coyne PJ, Parker GL, Dodson P, Fletcher DS</AU>
<TI>Testing the cutaneous absorption of lorazepam, diphenhydramine and haloperidol gel (ABH gel) used for cancer-related nausea</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>15 Suppl</NO>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2012" MODIFIED="2014-08-15 12:23:29 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-15 12:23:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith T, Fletcher D, Coyne P, Ritter J, Dodson P, Parker G</AU>
<TI>ABH gel (Ativan, Benadryl, Diphenhydramine, Haloperidol, Haldol) is not absorbed from the skin of normal volunteers so cannot be effective against nausea</TI>
<SO>Journal of Pain &amp; Symptom Management</SO>
<YR>2012</YR>
<VL>43</VL>
<PG>375-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stuart_x002d_Harris--1983" MODIFIED="2009-05-03 15:10:03 +0100" MODIFIED_BY="[Empty name]" NAME="Stuart-Harris  1983" YEAR="1983">
<REFERENCE MODIFIED="2009-05-03 15:10:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stuart-Harris R, Buckman R, Starke I, Wiltshaw E</AU>
<TI>Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1983</YR>
<VL>59</VL>
<PG>500-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thangathurai-2010" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Thangathurai 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thangathurai D, Roffey P</AU>
<TI>Usefulness of droperidol as an anti-emetic in terminally ill cancer patients</TI>
<SO>Journal of Palliative Medicine</SO>
<YR>2010</YR>
<VL>13</VL>
<NO>8</NO>
<PG>939</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tramer-1999" MODIFIED="2009-05-03 15:14:45 +0100" MODIFIED_BY="[Empty name]" NAME="Tramer 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-03 15:14:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tramer MR, Walder B</AU>
<TI>Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic review</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1999</YR>
<VL>88</VL>
<PG>1354-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1992" MODIFIED="2009-05-03 15:16:31 +0100" MODIFIED_BY="[Empty name]" NAME="White 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-05-03 15:16:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White RM, Myers EM, Ashayeri E, Gumbs RV, Pressoir R</AU>
<TI>Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>1</NO>
<PG>45-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2011" MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-15 11:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang LPH</AU>
<TI>Abiraterone acetate: in metastatic castration-resistant prostate cancer</TI>
<SO>Drugs</SO>
<YR>2011</YR>
<VL>71</VL>
<NO>15</NO>
<PG>2067-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-11-12 13:52:03 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-11-12 13:52:03 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bentley-2001" NAME="Bentley 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bentley A, Boyd K</AU>
<TI>Use of clinical pictures in the management of nausea and vomiting</TI>
<SO>Palliative Medicine</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlisle-2006" MODIFIED="2014-03-24 11:10:40 +0000" MODIFIED_BY="[Empty name]" NAME="Carlisle 2006" TYPE="COCHRANE_REVIEW">
<AU>Carlisle J, Stevenson CA</AU>
<TI>Drugs for preventing postoperative nausea and vomiting</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-03-24 11:03:40 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-24 11:03:40 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004125.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davis-2010" MODIFIED="2010-06-14 16:00:25 +0100" MODIFIED_BY="[Empty name]" NAME="Davis 2010" TYPE="JOURNAL_ARTICLE">
<AU>Davis MP, Hallerberg G</AU>
<TI>A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>4</NO>
<PG>756-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edmonds-2001" NAME="Edmonds 2001" TYPE="JOURNAL_ARTICLE">
<AU>Edmonds P, Karlsen S, Khan S, Addington-Hall J</AU>
<TI>A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer</TI>
<SO>Palliative Medicine</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>287-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Food-and-Drug-Administration-2001" MODIFIED="2014-11-12 13:52:03 +0000" MODIFIED_BY="[Empty name]" NAME="Food and Drug Administration 2001" TYPE="OTHER">
<TI>Important drug warning</TI>
<SO>http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173778.htm</SO>
<YR>4 Dec 2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glare-2004" NAME="Glare 2004" TYPE="JOURNAL_ARTICLE">
<AU>Glare P, Pereira G, Kristjanson L, Stockler M, Tattersall M</AU>
<TI>Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2004</YR>
<VL>12</VL>
<PG>432-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grande-2000" MODIFIED="2014-08-15 12:25:46 +0100" MODIFIED_BY="[Empty name]" NAME="Grande 2000" TYPE="JOURNAL_ARTICLE">
<AU>Grande GE, Todd CJ</AU>
<TI>Why are trials in palliative care so difficult?</TI>
<SO>Palliative Medicine</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>1</NO>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Habib-2008" MODIFIED="2009-10-05 16:53:16 +0100" MODIFIED_BY="[Empty name]" NAME="Habib 2008" TYPE="JOURNAL_ARTICLE">
<AU>Habib AS, Gan TJ</AU>
<TI>Pro: the Food and Drug Administration black box warning on droperidol is not justified</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2008</YR>
<VL>106</VL>
<PG>1414-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hadley-2009" MODIFIED="2014-08-15 12:26:42 +0100" MODIFIED_BY="[Empty name]" NAME="Hadley 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hadley G, Derry S, Moore RA, Wee B</AU>
<TI>Can observational studies provide a realistic alternative to randomised controlled trials in palliative care?</TI>
<SO>Journal of Pain &amp; Palliative Care Pharmacotherapy</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>2</NO>
<PG>106-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirst-2001" MODIFIED="2014-08-15 12:26:52 +0100" MODIFIED_BY="[Empty name]" NAME="Hirst 2001" TYPE="COCHRANE_REVIEW">
<AU>Hirst A, Sloan R</AU>
<TI>Benzodiazepines and related drugs for insomnia in palliative care</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-03-24 11:02:31 +0000" MODIFIED_BY="Laila Tyrrell">
<IDENTIFIER MODIFIED="2014-03-24 11:02:31 +0000" MODIFIED_BY="Laila Tyrrell" TYPE="DOI" VALUE="10.1002/14651858.CD003346"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2014-08-15 12:27:01 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kao-2003" NAME="Kao 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kao LW, Kirk MA, Evers SJ, Rosenfeld SH</AU>
<TI>Droperidol, QT prolongation, and sudden death: what is the evidence?</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>4</NO>
<PG>546-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klinkenberg-2004" MODIFIED="2014-08-15 12:27:40 +0100" MODIFIED_BY="[Empty name]" NAME="Klinkenberg 2004" TYPE="JOURNAL_ARTICLE">
<AU>Klinkenberg M, Willems DL, van der Wal G, Deeg DJH</AU>
<TI>Symptom burden in the last week of life</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>5-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ludwin-2008" MODIFIED="2009-10-05 16:53:39 +0100" MODIFIED_BY="[Empty name]" NAME="Ludwin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ludwin DB, Shafer SL</AU>
<TI>Con: the black box warning on droperidol should not be removed (but should be clarified!)</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2008</YR>
<VL>106</VL>
<PG>1418-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mannix-2004" NAME="Mannix 2004" TYPE="BOOK_SECTION">
<AU>Mannix KA</AU>
<TI>Palliation of nausea and vomiting</TI>
<SO>Oxford Textbook of Palliative Medicine</SO>
<YR>2004</YR>
<PB>Oxford University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martindale-2009" MODIFIED="2014-08-15 12:28:11 +0100" MODIFIED_BY="[Empty name]" NAME="Martindale 2009" TYPE="OTHER">
<AU>Martindale</AU>
<TI>The complete drug reference</TI>
<SO>www.medicinescomplete.com/mc/martindale/current</SO>
<YR>2009 (accessed 3 February 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKeage-2006" MODIFIED="2009-05-04 18:43:56 +0100" MODIFIED_BY="[Empty name]" NAME="McKeage 2006" TYPE="JOURNAL_ARTICLE">
<AU>McKeage K, Simpson D, Wagstaff AJ</AU>
<TI>Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting</TI>
<SO>Drugs</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>16</NO>
<PG>2123-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MHRA-2001" MODIFIED="2014-08-15 12:28:47 +0100" MODIFIED_BY="[Empty name]" NAME="MHRA 2001" TYPE="OTHER">
<AU>Medicines and Healthcare products Regulatory Agency</AU>
<TI>Discontinuation of Droleptan tablets, suspension and injection (droperidol)</TI>
<SO>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON019548</SO>
<YR>11 January 2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MHRA-2008" MODIFIED="2009-10-05 16:54:07 +0100" MODIFIED_BY="[Empty name]" NAME="MHRA 2008" TYPE="OTHER">
<AU>Medicines and Healthcare products Regulatory Agency</AU>
<TI>Marketing authorisations granted in January 2008</TI>
<SO>http://www.mhra.gov.uk/home/groups/l-reg/documents/licensing/con014139.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nuttall-2007" MODIFIED="2014-08-15 12:31:41 +0100" MODIFIED_BY="[Empty name]" NAME="Nuttall 2007" TYPE="JOURNAL_ARTICLE">
<AU>Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Shirk Marienau ME, et al</AU>
<TI>Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and Torsade de Pointes in the general surgical population?</TI>
<SO>Anesthesiology</SO>
<YR>2007</YR>
<VL>107</VL>
<PG>531-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perkins-2009" MODIFIED="2014-03-24 11:15:25 +0000" MODIFIED_BY="[Empty name]" NAME="Perkins 2009" TYPE="COCHRANE_REVIEW">
<AU>Perkins P, Dorman S</AU>
<TI>Haloperidol for the treatment of nausea and vomiting in palliative care patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-03-24 11:15:25 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-24 11:15:25 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006271.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rhodes-2001" NAME="Rhodes 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rhodes VA, McDaniel RW</AU>
<TI>Nausea, vomiting and retching: complex problems in palliative care</TI>
<SO>CA: A Cancer Journal for Clinicians</SO>
<YR>2001</YR>
<VL>51</VL>
<PG>232-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Twycross-1998" MODIFIED="2008-08-05 10:31:15 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Twycross 1998" TYPE="JOURNAL_ARTICLE">
<AU>Twycross R, Back I</AU>
<TI>Nausea and vomiting in advanced cancer</TI>
<SO>European Journal of Palliative Care</SO>
<YR>1998</YR>
<VL>5</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wee-2008" MODIFIED="2010-01-06 18:52:33 +0000" MODIFIED_BY="[Empty name]" NAME="Wee 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wee B, Hadley G, Derry S</AU>
<TI>How useful are systematic reviews for informing palliative care practice? Survey of 25 Cochrane systematic reviews</TI>
<SO>BMC Palliative Care</SO>
<YR>2008</YR>
<VL>7</VL>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-08-15 14:13:48 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Dorman-2010" MODIFIED="2014-08-15 14:13:48 +0100" MODIFIED_BY="[Empty name]" NAME="Dorman 2010" TYPE="COCHRANE_REVIEW">
<AU>Dorman S, Perkins P</AU>
<TI>Droperidol for treatment of nausea and vomiting in palliative care patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2014-02-03 16:39:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-03 16:39:20 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006938.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-10-04 18:59:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Aapro-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Underlying diagnoses not clear. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Aldrete-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults suffering from an incurable progressive medical condition</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Braude-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Any diagnosis causing nausea or vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Casey-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Not a RCT; not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:45:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheung-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:45:01 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Dale-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Not a RCT; not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:45:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Etievant-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:45:27 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol, nausea or vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:45:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feyer-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:45:50 +0000" MODIFIED_BY="[Empty name]">
<P>Prophylaxis and treatment of chemotherapy-induced nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Fujii-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:46:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Getto-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:46:23 +0000" MODIFIED_BY="[Empty name]">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:46:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glare-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:46:34 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:47:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzales-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:47:14 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:47:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hardy-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:47:22 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Herrstedt-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Jacobs-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition (stage of cancers not documented). Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Kim-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Prophylaxis of interleukin-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Lehoczky-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Not randomised. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Lennox-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting. Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Lewis-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:47:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McHugh-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:47:38 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-03 17:31:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McNicol-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-03 17:31:54 +0100" MODIFIED_BY="[Empty name]">
<P>Systematic review rather than randomised controlled trial. Not specific to droperidol, nausea or vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Melsom-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Minegishi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition (stage of cancers not documented). Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Muller-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Inadequate detail to assess population (abstract only), but not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Niijima-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:47:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Connor-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:47:54 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Owens-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-15 12:13:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patanwala-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-15 12:13:43 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised. Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Poka-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:49:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richards-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:49:35 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol, nausea or vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Roberts-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Sagae-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Saller-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:49:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:49:53 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:50:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:50:00 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:50:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:50:11 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Stuart_x002d_Harris--1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:50:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thangathurai-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:50:21 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Tramer-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of postoperative nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-White-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-17 11:37:43 +0000" MODIFIED_BY="Anna Hobson">
<P>Not a RCT - groups treated sequentially. Prophylaxis of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-03 16:50:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-03 16:50:39 +0000" MODIFIED_BY="[Empty name]">
<P>Not specific to droperidol, nausea or vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-10-04 18:59:49 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-10-04 18:59:49 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2014-08-15 14:11:57 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-08-15 14:11:57 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAAL4CAYAAADvSZayAABgqUlEQVR42uzdD4RWef8//g9ZSVaW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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-10-08 18:24:50 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-10-08 18:24:50 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-08-05 10:29:19 +0100" MODIFIED_BY="Laila Tyrrell">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-10-08 18:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>1. RANDOMIZED CONTROLLED TRIAL.pt.<BR/>2. CONTROLLED CLINICAL TRIAL.pt.<BR/>3. RANDOMIZED CONTROLLED TRIALS.sh.<BR/>4. RANDOM ALLOCATION.sh.<BR/>5. DOUBLE BLIND METHOD.sh.<BR/>6. SINGLE BLIND METHOD.sh.<BR/>7. 1 or 2 or 3 or 4 or 5 or 6<BR/>8. (ANIMALS not HUMAN).sh.<BR/>9. 7 not 8<BR/>10. CLINICAL TRIAL.pt.<BR/>11. exp CLINICAL TRIALS/<BR/>12. (clin$ adj25 trial$).ti,ab.<BR/>13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>14. PLACEBOS.sh.<BR/>15. placebo$.ti,ab.<BR/>16. random$.ti,ab.<BR/>17. RESEARCH DESIGN.sh.<BR/>18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17<BR/>19. 18 not 8<BR/>20. 19 not 9<BR/>21. COMPARATIVE STUDY.sh.<BR/>22. exp EVALUATION STUDIES/<BR/>23. FOLLOW UP STUDIES.sh.<BR/>24. PROSPECTIVE STUDIES.sh.<BR/>25. (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>26. 21 or 22 or 23 or 24 or 25<BR/>27. 26 not 8<BR/>28. 27 not (9 or 20)<BR/>29. 9 or 20 or 28<BR/>30. nause$.mp.<BR/>31. vomit$.mp.<BR/>32. emesis.mp.<BR/>33. emet$.mp.<BR/>34. anti-eme$.mp.<BR/>35. antieme$.mp.<BR/>36. antiemetics.sh.<BR/>37. nausea.sh.<BR/>38. vomiting.sh.<BR/>39. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38<BR/>40. droperidol.mp.<BR/>41. droleptan$.mp.<BR/>42. dehydrobenzperidol$.mp.<BR/>43. droperdal$.mp.<BR/>44. inapsine$.mp.<BR/>45. droperol$.mp.<BR/>46. sintodian$.mp.<BR/>47. dridol$.mp.<BR/>48. inapsin$.mp.<BR/>49. paxical$.mp.<BR/>50. dehidrobenzperidol$.mp.<BR/>51. 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50<BR/>52. butyrophenone$.mp.<BR/>53. exp butyrophenones/<BR/>54. 52 or 53<BR/>55. 51 or 54<BR/>56. 29 and 39 and 55</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 NEW studies included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;18 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;261 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;261 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;304 records identified through database searching (2009 to 2013)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;243 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;18 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>